Compare Adaptive Biotechnologies Corp (ADPT) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Waste Management, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.17 (market cap $4.04B), while Waste Management, Inc. trades at $226.7 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 22.4× Adaptive Biotechnologies Corp's market cap, and Waste Management, Inc. pays a 1.56% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WM | |
|---|---|---|
Market Cap | $4.04B | $90.68B |
Sector | Health | Industrials |
52-Week High | $25.45 | $246.51 |
52-Week Low | $12.30 | $196.77 |
Enterprise Value | $4.10B | $113.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
WM trades at $226.6, down 0.47% over 24 hours, with a bullish technical signal and support near $226. The stock shows strong profitability with a 40.6% gross margin and 11.12% net margin, though its P/E of 59.74 is elevated. Recent Q2 2026 earnings beat expectations at $2.02 per share, and analyst consensus is a buy with a $263.43 price target. Cash flow from operations grew to $6.04B in 2025, but net cash flow was negative $190M due to investments.
Outlook is positive with revenue growth and margin stability, but risks include high valuation and debt levels. The stock offers upside to the consensus target, supported by institutional confidence and consistent earnings beats, though investors should monitor volume trends and interest rate impacts on borrowing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
